Een Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies relating to withdrawal of chloroquine? Acta Trop 2012, 121:148?51. 28. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G: Efficacy of artemether-lumefantrine in remedy of malaria amongst under-fives and prevalence of drug resistance markers in IgombeMwanza, north-western Tanzania. Malar J 2012, 11:58. 29. Eriksen J, Nsimba SE, Minzi OM, Sanga AJ, Petzold M, Gustafsson LL, Warsame MY, Tomson G: Adoption from the new antimalarial drug policy in Tanzania cross-sectional study inside the neighborhood. Trop Med Int Well being 2005, 10:1038?046. 30. Thomsen TT, Madsen LB, Hansson HH, Tomas EV, Charlwood D, Bygbjerg IC, Alifrangis M: Fast selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with previous chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique.1-(Difluoromethyl)-4-iodo-1H-pyrazole custom synthesis Am J Trop Med Hyg 2013, 88:536?41. 31. Kiwuwa MS, Byarugaba J, Wahlgren M, Kironde F: Detection of copy quantity variation and single nucleotide polymorphisms in genes involved in drug resistance along with other phenotypic traits in P.Buy4-Methoxy-2-methylpyrimidin-5-amine falciparum clinical isolates collected from Uganda.PMID:23357584 Acta Trop 2013, 125:269?75. 32. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ: In vitro sensitivities of Plasmodium falciparum to distinctive antimalarial drugs in Uganda. Antimicrob Agents Chemother 2010, 54:1200?206. 33. Enosse S, Magnussen P, Abacassamo F, Gomez-Olive X, Ronn AM, Thompson R, Alifrangis M: Fast boost of Plasmodium falciparum dhfr/dhps resistant haplotypes, soon after the adoption of sulphadoxinepyrimethamine as very first line therapy in 2002, in southern Mozambique. Malar J 2008, 7:115. 34. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI: Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS A single 2011, six:e25992. 35. Frosch AE, Venkatesan M, Laufer MK: Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic critique of household survey and molecular data. Malar J 2011, 10:116.36. Ucakacon PS, Achan J, Kutyabami P, Odoi AR, Kalyango NJ: Prescribing practices for malaria inside a rural Ugandan hospital: evaluation of a brand new malaria therapy policy. Afr Overall health Sci 2011, 11(1):53?9. 37. Kallander K, Tomson G, Nsungwa-Sabiiti J, Senyonjo Y, Pariyo G, Peterson S: Neighborhood referral in property management of malaria in western Uganda: a case series study. BMC Int Wellness Hum Rights 2006, 6:two. 38. Nanyunja M, Nabyonga OJ, Kato F, Kaggwa M, Katureebe C, Saweka J: Malaria therapy policy adjust and implementation: the case of Uganda. Malar Res Treat 2011, 2011:683167. 39. Noor AM, Rage IA, Moonen B, Snow RW: Overall health service providers in Somalia: their readiness to provide malaria case-management. Malar J 2009, 8:100. 40. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M: Prevalence of single nucleotide polymorphisms inside the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania just before and soon after introduction of artemisinin-based combination therapy. Am J Trop Med Hyg 2011, 85:979?83. 41. WHO-MPAC: Malaria Policy Advisory Committee for the WHO: conclusions and recommendations of March 2013 meeting. Malar J 2013, 12:213. 42. Vleugels MP, Wetsteyn JC, Meuwissen JH: Fansida.